However, although many tumor suppressor or oncogenic miRNAs targeting CXCR4 have been identified [200], their clinical applications have been hampered mainly due to oligonucleotide degradation in the bloodstream and off-target toxicities [206]. The gene discussed is CXCR4; the disease is neoplasm.